Our findings reveal that pharmacological inhibition of FAK in combination with RAF/MEK inhibition significantly suppresses melanoma growth, reduces the development of metastases in preclinical mouse models, and prolongs survival in mice with existing brain metastases. Here, PTK2 is linked to melanoma.